Alan Meds vs Roen Rx
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Alan Meds
Best for budget-conscious shoppersStarting at $99/mo
Roen Rx
Best for patients with insurance seeking brand-name GLP-1 access with compounded fallbackStarting at $25/mo
Side-by-Side Comparison
| Feature | Alan Meds | Roen Rx |
|---|---|---|
| Overall Score | ✓7.7/10 | 7.0/10 |
| Starting Price | $99/mo | ✓$25/mo |
| Editorial Rating | ✓3.9 ★ /5 | 3.5 ★ /5 |
| Features | 5 features | ✓7 features |
| States Available | ✓46 | 0 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | — | ✓ Yes |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
Alan Meds
Pros
- ✓Aggressively low monthly pricing
- ✓Both semaglutide and tirzepatide available
- ✓Compounded GLP-1 access
- ✓Multiple administration formats
Cons
- ✗Limited public information on program details
Roen Rx
Pros
- ✓Insurance coordination for brand-name GLP-1s — as low as $25/mo
- ✓Both compounded and brand-name options
- ✓LegitScript approved with Compounded USA badge
- ✓Compounded semaglutide from $151/mo quarterly
- ✓Also offers primary care, mental health, and other specialties
Cons
- ✗State availability not publicly disclosed
- ✗Insurance coordination may not work for all plans
- ✗Broader platform (ED, hair loss, skincare, birth control)
Our Verdict
Alan Meds edges out Roen Rx with a higher overall score of 7.7/10 and is particularly strong for budget-conscious shoppers. Roen Rx remains a solid alternative, especially if you're looking for patients with insurance seeking brand-name GLP-1 access with compounded fallback.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.